Establishment and identification of patient-derived organoid model in head and neck squamous carcinoma

doi:10.19438/j.cjoms.2022.04.003

Abstract

Abstract: PURPOSE: To construct and identify patient-derived organoid (PDO) model of head and neck squamous cell carcinoma(HNSCC). METHODS: Tumor cells, isolated from HNSCC samples, were cultured and passaged in matrix gel with three dimensions. The growth was also recorded at regular intervals. The correlation between patient tumor tissue and PDO models in histopathological and tumor molecular markers was compared using H-E and immunohistochemical staining assay. RESULTS: This study displayed 3 cases of PDO models that could be passaged stably, and the histopathology and tumor marker identification results showed that the model and the patient's tissues were consistent with each other. CONCLUSIONS: The PDO model constructed from samples of HNSCC could reflect the patient's histomorphology and biomarker characteristics, and could be utilized as a reliable preclinical model in the further HNSCC study.

Key words: Head and neck squamous cell carcinoma, Patient-derived organoid, Preclinical model

CLC Number:

R739.8

WANG Chong, KANG Xin-dan, WANG Rui, WU Ya-ping, SUN Lu-lu, ZHANG Zhi-yuan, SUN Shu-yang. Establishment and identification of patient-derived organoid model in head and neck squamous carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 328-333.

References

[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Chen W, Zheng R, Baade P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Rajasagi M, Shukla SA, Fritsch EF, et al.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia[J]. Blood, 2014, 124(3): 453-462.
[4] Chow LQM.Head and neck cancer[J]. N Engl J Med, 2020, 382(1): 60-72.
[5] Ferris RL, Blumenschein G, Fayette J, et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867.
[6] Haddad RI, Shin DM.Recent advances in head and neck cancer[J]. N Engl J Med, 2008, 359(11): 1143-1154.
[7] Cramer JD, Burtness B, Le QT, et al.The changing therapeutic landscape of head and neck cancer[J]. Nat Rev Clin Oncol, 2019, 16(11): 669-683.
[8] Souza AG, Silva IBB, Campos-Fernandez E, et al.Comparative assay of 2D and 3D cell culture models: proliferation, gene expression and anticancer drug response[J]. Curr Pharm Des, 2018, 24(15): 1689-1694.
[9] Friedrich J, Seidel C, Ebner R, et al.Spheroid-based drug screen: considerations and practical approach[J]. Nat Prot, 2009, 4(3): 309-324.
[10] Howes AL, Chiang GG, Lang ES, et al.The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures[J]. Mol Cancer Ther, 2007, 6(9): 2505-2514.
[11] Hidalgo M, Amant F, Biankin AV, et al.Patient-derived xenograft models: an emerging platform for translational cancer research[J]. Cancer Discov, 2014, 4(9): 998-1013.
[12] Stewart EL, Mascaux C, Pham NA, et al.Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma[J]. J Clin Oncol, 2015, 33(22): 2472-2480.
[13] Gao H, Korn J, Ferretti S, et al.High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response[J]. Nat Med, 2015, 21(11): 1318-1325.
[14] Palechor-Ceron N, Krawczyk E, Dakic A, et al.Conditional reprogramming for patient-derived cancer models and next-generation living biobanks[J]. Cells, 2019, 8(11): 1327-1351.
[15] Rossi G, Manfrin A, Lutolf MP.Progress and potential in organoid research[J]. Nat Rev Genet, 2018, 19(11): 671-687.
[16] Drost J, Clevers H.Organoids in cancer research[J]. Nat Rev Cancer, 2018, 18(7): 407-418.
[17] Lancaster MA, Knoblich JA.Organogenesis in a dish: modeling development and disease using organoid technologies[J]. Science, 2014, 345(6194): 1247125.
[18] Driehuis E, Kolders S, Spelier S, et al.Oral mucosal organoids as a potential platform for personalized cancer therapy[J]. Cancer Discov, 2019, 9(7): 852-871.
[19] Tanaka N, Osman AA, Takahashi Y, et al.Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity[J]. Oral Oncol, 2018, 87: 49-57.
[20] Bartfeld S, Bayram T, Van De Wetering M, et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection[J]. Gastroenterology, 2015, 148(1):126-136.e6.
[21] Scanu T, Spaapen RM, Bakker JM, et al.Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma[J]. Cell Host Microbe, 2015, 17(6): 763-774.
[22] Dijkstra KK, Cattaneo CM, Weeber F, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids [J]. Cell, 2018, 174(6): 1586-1598.e12.
[23] Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment [J]. Cell, 2018, 175(7): 1972-1988.e16.
[24] Torre L, Bray F, Siegel R, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[25] Mroz EA, Tward AD, Pickering CR, et al.High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma[J]. Cancer, 2013, 119(16): 3034-3042.
[26] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南[M]. 北京: 人民卫生出版社, 2021.
Guideline Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of head and neck tumors[M]. Beijing: People's Medical Publishing House,2021.
[27] Burtness B, Harrington K, Greil R, et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet (London, England), 2019, 394(10212): 1915-1928.